2 June 2025 – Melbourne, Australia | ReNerve Limited (ASX:RNV) has today announced a strategic partnership with US-based Berkeley Biologics, focused on developing and commercialising two new tissue-based product ranges, which will significantly expand its surgical offering in the peripheral nerve injury (PNI) space.
The collaboration between the organisations will see both product lines launched in the United States market in 2025, complementing ReNerve’s existing portfolio and enabling deeper engagement with its surgeon and hospital network throughout the nation.
Highlights:
-
New strategic partnership with Berkeley Biologics, focused on launching two tissue-based product ranges.
-
Dermal tissue and amniotic tissue product ranges.
-
-
First product line currently targeting Q3 2025 market launch, and the second range by year-end.
-
Approvals already achieved in the US and the products will be manufactured at Berkeley’s facility located in California.
-
The partnership involves a five-year supply agreement being signed, with the option to extend.
-
Products are to be distributed through ReNerve’s existing channels and used in procedures related to trauma, orthopaedics, plastic surgery, and nerve repair.
-
Live webinar with Dr Juilian Chick will be held on Tuesday, 3 June at 11:00am AEST.
-
Focused on discussing the partnership and answering questions.
-
Registration is available at: https://bit.ly/RNV-3-June-2025
-
The partnership brings to market new dermal tissue and amniotic tissue product ranges, both widely used in wound care and reconstructive procedures. These products are highly complementary to ReNerve’s existing NervAlign® line, addressing related surgical needs often encountered in conjunction with nerve repair.
Commenting on the new partnership with Berkeley Biologics and the new product ranges, ReNerve Director, Dr Julian Chick, stated: “The rationale for this partnership is to build-out the product offerings that ReNerve can provide to surgeons, patients and hospitals. The products we are looking to launch this year are used by the existing and new customers for ReNerve's peripheral nerve product range. Surgeons that work on nerve repairs also undertake other types of surgery, where they are required to repair not only damaged nerves. With these two new product lines, the Company can offer surgeons, hospitals and patients a more complete product range for all the tissues that are required for surgery."
A live investor webinar hosted by Dr Chick will be held on Tuesday, 3 June at 11:00am AEST to discuss the partnership and answer questions.
Registration is available at: https://bit.ly/RNV-3-June-2025
About Berkeley Biologics
Berkeley Biologics develops innovative biologics and wound care products that support healing and regeneration in bone and soft tissue. Its product portfolio serves specialties including orthopaedics, spine, trauma, dental, and wound care. Known for its commitment to safety, quality, and honouring tissue donation, Berkeley Biologics manufactures its products in California and is a trusted partner to healthcare providers across the US.
For further information, please contact:
Dr Julian Chick
CEO & Managing Director
[email protected]
Jane Morgan
Investor & Media Relations
Jane Morgan Management
[email protected]
About us:
About ReNerve Limited (ASX:RNV)
ReNerve Limited is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]
